Major Shareholder Disputes Validity of Recent Share Issuances, Claims 33% Stake
SLXN has more than doubled off its 52-week low of $2.31.
Summary
A major investor, Moringa Sponsor, LP, is disputing the validity of 1.375 million shares issued by Silexion Therapeutics, representing nearly all of its 33% ownership stake, indicating a significant corporate governance conflict.
Key Events · Ownership and Investor Activity · SLXN
-
Major Shareholder Dispute
Moringa Sponsor, LP, a 32.99% owner, is disputing the validity of 1,375,004 ordinary shares issued by the company on September 15, 2025, and May 14, 2026. These shares are equivalent to 137,500 post-split shares.
-
Significant Ownership Stake
The reporting group, including Moringa Sponsor, LP and Ilan Levin, collectively reports beneficial ownership of 138,234 post-split shares, representing 32.99% of the company's outstanding ordinary shares.
-
Conversion of Promissory Note
The disputed shares were issued upon conversion of an aggregate of $2.2 million from an Amended and Restated Promissory Note.
-
Legal Uncertainty
The explicit dispute over share validity introduces significant legal and corporate governance uncertainty for the company, which is already under a "going concern" warning.
Analysis · SLXN · Life Sciences
A significant shareholder, Moringa Sponsor, LP, has filed an amendment to its Schedule 13D, explicitly disputing the validity of 1,375,004 ordinary shares recently issued by Silexion Therapeutics Corp. These shares, converted from a promissory note, represent almost the entirety of Moringa's reported 32.99% stake. This dispute signals a major conflict between a key investor and the company, potentially leading to litigation and further destabilizing a company already facing severe financial challenges and a recent reverse stock split.
How filings like this one have moved
In the 30 days to Sep 8, 2026, 45.2% of the 628 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $4.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $2.31 to $223.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.